



Caelyx advertisement.


[s.l.]: [s.n.], 1949

<https://digital.library.wisc.edu/1711.dl/VF5WSO2LRTSMZ9A>

<http://rightsstatements.org/vocab/InC/1.0/>

The libraries provide public access to a wide range of material, including online exhibits, digitized collections, archival finding aids, our catalog, online articles, and a growing range of materials in many media.

When possible, we provide rights information in catalog records, finding aids, and other metadata that accompanies collections or items. However, it is always the user's obligation to evaluate copyright and rights issues in light of their own use.



A New Opportunity for Your Ovarian Cancer Patient

Indication;

Advanced ovarian cancer in women who have failed a first-line platinum-based chemotherapy regimen

Ref. "Recurrent Epithelial Ovarian Carcinoma: A Randomized Phase III Study of Pegylated Liposomal Doxorubicin Versus Topotecan" Alan N. Gordon et al. J. of Clinical Oncology, Vol 19, No 14 (July 15) 2001.

www.caelyx.nu



Schering-Plough Nordic Biotech

Phone +46 (0)8 522 21 500.

Fax +46 (0)8 522 21 661.

www.schering-plough.se